Published in final edited form as:

Chem Commun (Camb). 2011 January 7; 47(1): 427–429. doi:10.1039/c0cc02214d.

Revisiting the Kinnel–Scheuer hypothesis for the biosynthesis of palau'amine^{†,‡}

Zhiqiang Ma, Jianming Lu, Xiao Wang, and Chuo Chen*

Department of Biochemistry, UT Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390-9038, USA

Abstract

We propose herein an alternative biosynthetic pathway for palau'amine in order to resolve the stereochemical issue from the original Kinnel–Scheuer hypothesis. Furthermore, we use this revised hypothesis as a guide toward the laboratory synthesis of palau'amine.

Dimeric pyrrole-imidazole alkaloids¹ form a class of structurally unique marine natural products that have, over the past decades, inspired chemists to develop numerous synthetic strategies and methods.^{2,3} In particular, the recent completion of the syntheses of the [3+2] dimers axinellamines,⁴ massadines,⁵ and palau'amine⁶ by the Baran group stands as a landmark in modern synthesis. The biosynthetic pathway of these pyrrole-imidazole dimers has also been proposed.⁷ We present herein a plausible biosynthetic pathway of palau'amine (**1**), and use it as a strategy for the laboratory synthesis of **1**.

Kinnel, Scheuer, and co-workers have suggested in their isolation paper that “palau'amine” (**2**) may arise from a [4+2] cycloaddition of 3-amino-1-(2-aminoimidazolyl)prop-1-ene (**3**) and 11,12-dehydrophakellin (**4**), followed by a chloro-peroxidase-mediated chlorination and ring contraction (Scheme 1).^{7C} However, the structure of palau'amine was recently revised from **2** to **1**.⁸ The C-11/C-12 *anti* stereochemistry in **1** cannot easily be explained by this proposed pathway. The thermal Diels–Alder reaction pathway will result in a *syn* stereochemistry, and the photo Diels–Alder reaction pathway is not likely considering the lack of sufficient UV-light to the sponges.^{7a} Meanwhile, the difficulty in constructing the piperazine moiety of **1** at a late stage^{6,9} indicates that this transformation is highly endothermic, and requires significant energy input. We therefore suspected that the ring strain of **1** may be introduced stepwise, both biosynthetically and synthetically.

In addition to Baran's macrocycle strategy,⁶ we consider the original Kinnel–Scheuer hypothesis a viable pathway. To reconcile the stereochemical issue of the [4+2] cycloaddition, we propose the intermediacy of ageliferin analog **7** (Scheme 1). Specifically, a [4+2] cycloaddition reaction of **3** and clathrodin (**6**) would give rise to **7**, and set the *anti* C-11/C-12 stereochemistry. An oxidative bicyclization would then provide the modified Kinnel–Scheuer intermediate **8**, which could undergo a chlorinative ring contraction to afford **1**. We have synthesized **9**, a close analog of **8**, in its protected form as a step toward the laboratory synthesis of **1**.

[†]This article is part of the 'Emerging Investigators' themed issue for ChemComm.

[‡]Electronic supplementary information (ESI) available: Experimental procedures and characterization data.

Chuo.Chen@UTSouthwestern.edu; Fax: 214 648 0320; Tel: 214 648 5048.

Central to our synthetic strategy is a Mn(III)-mediated oxidative radical cyclization reaction,^{10,11} that, in an intramolecular way, resembles the biogenic [4+2] dimerization to construct the cyclohexenyl core of **7** (Scheme 2). Specifically, oxidation of β -ketoester **15** with Mn(OAc)³ initiated a cascade radical cyclization sequence to deliver **16** that bears the ageliferin skeleton. Two C–C bonds (C-11/C-20 and C-12/C-18) and three stereogenic centers (C-11, C-12, and C-18) were established in this single transformation.

To construct **15**, we used a convergent approach that comprises an aldol reaction between aldehyde **11** and ester **14** (LiHMDS, THF; 79% over three steps), and an alcohol oxidation (Dess–Martin periodinane, H₂O, CH₂Cl₂). Aldehyde **11** was prepared in one-pot from imidazole (**10**) (NaH, BOMCl, DMF, then NaH, CuCl₂, O₂, then POCl₃; 68%). Ester **14** was prepared from coupling (DCC, CH₂Cl₂) of Cbz- β -Ala-OH with the known alcohol **13**, which was in turn synthesized in two steps from Garner's aldehyde (**12**) (i) Ph₃P=CHCOOMe, benzene; (ii) DIBAL, THF) according to the literature.¹²

Treating β -ketoester **15** with Mn(OAc)₃ in warm acetic acid results in a quite clean transformation. The ageliferin core skeleton **16** was obtained as the only diastereomer in 36% yield over two steps from the aldol product of **11** and **14**.¹³ The stereochemical course of this reaction was controlled by the C-10 stereogenic center through an A^{1,3} strain.¹⁰ The ester tether, used for the intramolecular Mn(III) oxidation reaction, was then removed. The decarboxylation (LiOH, THF, H₂O) of **16** gave rise to a product with *cis*-C-12/C-18 stereochemistry as the thermodynamic product. The N-14 nitrogen atom was then introduced as an azide by a Mitsunobu reaction ((PhO)₂P(O)N₃, DEAD, PPh₃, THF; 42% for two steps). The C-18 stereocenter was subsequently epimerized through kinetic protonation of the corresponding enolate (LiHMDS, THF, then HOAc) and the C-17 carbonyl group was deoxygenated (Ca(BH₄)₂, THF,¹⁴ then NaBH₃CN, HOAc) to afford **17**.

In order to implement the oxidative bicyclization strategy to install the piperazine ring, we converted the C-11 side chain of **17** to an imidazolinone group by a three-pot procedure. The acetonide protecting group was first removed (TFA, CH₂Cl₂) and the resulting alcohol was oxidized (Dess–Martin periodinane, H₂O, CH₂Cl₂). The Boc protecting group was next removed under acidic conditions, followed by *in situ* treatment of the amino aldehyde with potassium cyanate at pH 4 to afford **18** (HCl, MeOH, H₂O, then *o*-(HO₂C)C₆H₄(CO₂K), NaOH, KOCN).¹⁵ It is noteworthy that Myers and co-workers have previously reported that amino aldehydes are stable in aqueous media below pH 5, with the aldehyde group existing in its hydrate form.¹⁶ In our hands, buffering the aqueous methanol solution of the amino aldehyde with potassium hydrogen phthalate gave the best results.

With **18** in hand, we next sought to introduce the pyrrole group and set the stage for the oxidative bicyclization. The azido group was reduced by a Staudinger reduction (PPh₃, H₂O, THF) and the product was obtained in 7–10% yield over 6 steps after HPLC purification. The pyrrole group was then installed ((Br₂-Pyrrole)COCCl₃, NEt₃, DMF; 33%). Use of a less pure amine for this reaction resulted in significantly less or no product.

We previously reported a hypervalent iodine(III)-mediated oxidative bicyclization reaction of dihydro-14-oxo-oroidin to give dibromophakellstatin in quantitative yield.¹⁷ Pleasingly, use of the same reaction conditions (PhI(OAc)₂, Na₂CO₃, TFE) to oxidize **19** did afford **20**, though inconsistently in 0–5% yield. After extensive optimization, we found PhIO to be a better oxidant, which gave rise to an unstable product that slowly converted to the Kinnel–Scheuer intermediate analog **20** at elevated temperature in DMSO in 20% yield over two steps. A similar unstable intermediate, which was suspected to be the monocyclized product, was also observed by Büchi and co-workers when oxidizing dihydrooroidin with bromine to form dibromophakellin.^{15b,18}

In summary, as part of our palau'amine synthesis project, we have synthesized a close analog of the modified Kinnel–Scheuer intermediate from their biosynthesis proposal. The stereochemistry of this advanced synthetic intermediate is consistent with the revised structure of palau'amine. The biomimetic oxidative ring contraction of the Kinnel–Scheuer intermediate has previously been realized in model systems in the laboratory by Romo,^{3d} Lovely,^{3c} Baran¹⁹ and us.¹⁰ In particular, the method developed by Romo allowed for the introduction of the chlorine atom. We are currently examining the practicality of these methods in converting advanced synthetic intermediates such as **20** into palau'amine (**1**).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the NIH (Grant NIGMS R01-GM079554), the Welch Foundation (I-1596), and UT Southwestern for financial support, and Prof. Joseph Fox (University of Delaware) for the suggestion of the use of ethyltrichlorosilane-deactivated silica gel.

Notes and references

§ This biosynthetic pathway was a “better alternative” suggested by a reviewer of ref. ^{7c}.

1. Forte B, Malgesini B, Piutti C, Quartieri F, Scolaro A, Papeo G. *Mar Drugs* 2009;7:705–753. [PubMed: 20098608]
2. (a) Gaich T, Baran PS. *J Org Chem* 2010;75:4657–4673. [PubMed: 20540516] (b) Heasley B. *Eur J Org Chem* 2009:1477–1489. (c) Arndt HD, Riedrich M. *Angew Chem, Int Ed* 2008;47:4785–4788. (d) Köck M, Grube A, Seiple IB, Baran PS. *Angew Chem, Int Ed* 2007;46:6586–6594. (e) Jacquot DEN, Lindel T. *Curr Org Chem* 2005;9:1551–1565. (f) Hoffmann H, Lindel T. *Synthesis* 2003:1753–1783.
3. For example: (a) Overman LE, Rogers BN, Tellew JE, Trenkle WC. *J Am Chem Soc* 1997;119:7159–7160. (b) Starr JT, Koch G, Carreira EM. *J Am Chem Soc* 2000;122:8793–8794. (c) Lovely CJ, Du H, Dias HVR. *Org Lett* 2001;3:1319–1322. [PubMed: 11348224] (d) Dilley AS, Romo D. *Org Lett* 2001;3:1535–1538. [PubMed: 11388860] (e) Kawasaki I, Sakaguchi N, Fukushima N, Fujioka N, Nikaido F, Yamashita M, Ohta S. *Tetrahedron Lett* 2002;43:4377–4380. (f) Koenig SG, Miller SM, Leonard KA, Löwe RS, Chen BC, Austin DJ. *Org Lett* 2003;5:2203–2206. [PubMed: 12816409] (g) Baran PS, Zografos AL, O'Malley DP. *J Am Chem Soc* 2004;126:3726–3727. [PubMed: 15038721] (h) Baran PS, O'Malley DP, Zografos AL. *Angew Chem, Int Ed* 2004;43:2674–2677. (i) Birman VB, Jiang XT. *Org Lett* 2004;6:2369–2371. [PubMed: 15228281] (j) Garrido-Hernandez H, Nakadaï M, Vimolratana M, Li Q, Doundoulakis T, Harran PG. *Angew Chem, Int Ed* 2005;44:765–769. (k) Kawasaki I, Sakaguchi N, Khadeer A, Yamashita M, Ohta S. *Tetrahedron* 2006;62:10182–10192. (l) Bultman MS, Ma J, Gin DY. *Angew Chem, Int Ed* 2008;47:6821–6824. (m) Hudon J, Cernak TA, Ashenhurst JA, Gleason JL. *Angew Chem, Int Ed* 2008;47:8885–8888.
4. (a) Yamaguchi J, Seiple IB, Young IS, O'Malley DP, Maue M, Baran PS. *Angew Chem, Int Ed* 2008;47:3578–3580. (b) O'Malley DP, Yamaguchi J, Young IS, Seiple IB, Baran PS. *Angew Chem, Int Ed* 2008;47:3581–3583.
5. Su S, Seiple IB, Young IS, Baran PS. *J Am Chem Soc* 2008;130:16490–16491. [PubMed: 19049446]
6. Seiple IB, Su S, Young IS, Lewis CA, Yamaguchi J, Baran PS. *Angew Chem, Int Ed* 2009;49:1095–1098.
7. (a) Walker RP, Faulkner DJ, Engen DV, Clardy J. *J Am Chem Soc* 1981;103:6772–6773. (b) Keifer PA, Schwartz RE, Koker MES, Hughes JRG, Rittschof D, Rinehart KL. *J Org Chem* 1991;56:2965–2975. (c) Kinnel RB, Gehrken HP, Swali R, Skoropowski G, Scheuer PJ. *J Org Chem* 1998;63:3281–3286. (d) Al Mourabit A, Potier P. *Eur J Org Chem* 2001:237–243. (e) Ref. 3h; (f)

- Northrop BH, O'Malley DP, Zografos AL, Baran PS, Houk KN. *Angew Chem, Int Ed* 2006;45:4126–4130. (g) Pöverlein C, Breckle G, Lindel T. *Org Lett* 2006;8:819–821. [PubMed: 16494449]
8. (a) Buchanan MS, Carroll AR, Addepalli R, Avery VM, Hooper JNA, Quinn RJ. *J Org Chem* 2007;72:2309–2317. [PubMed: 17315930] (b) Buchanan MS, Carroll AR, Quinn RJ. *Tetrahedron Lett* 2007;48:4573–4574. (c) Grube A, Köck M. *Angew Chem, Int Ed* 2007;46:2320–2324. (d) Kobayashi H, Kitamura K, Nagai K, Nakao Y, Fusetani N, Soest RWMv, Matsunaga S. *Tetrahedron Lett* 2007;48:2127–2129.
9. Ma Z, Chen C. unpublished results.
10. Tan X, Chen C. *Angew Chem, Int Ed* 2006;45:4345–4348.
11. (a) Snider BB. *Chem Rev* 1996;96:339–363. [PubMed: 11848756] (b) Melikyan GG. *Org React* 1997;49:427–675.
12. (a) Lin S, Yang ZQ, Kwok BHB, Koldobskiy M, Crews CM, Danishefsky SJ. *J Am Chem Soc* 2004;126:6347–6355. [PubMed: 15149232] (b) Devel L, Hamon L, Becker H, Thellend A, Vidal-Cros A. *Carbohydr Res* 2003;338:1591–1601. [PubMed: 12860430]
13. While the crude ^1H NMR indicated **16** to be the only significant product, it was not stable to silica gel column chromatography, leading to its diminished isolated yield. The stereochemistry of **16** was assigned based on the stereochemical studies from ref. 10, and confirmed by ROESY experiments of subsequent synthetic intermediates.
14. (a) Kollonitsch J, Fuchs O, Gábor V. *Nature* 1954;173:125–126. (b) Brown HC, Narasimhan S, Choi YM. *J Org Chem* 1982;47:4702–4708.
15. (a) Wiese KJ, Yakushijin K, Horne DA. *Tetrahedron Lett* 2002;43:5135–5136. See also: (b) Foley LH, Büchi G. *J Am Chem Soc* 1982;104:1776–1777. (c) Ref. 3g.
16. Myers AG, Kung DW, Zhong B. *J Am Chem Soc* 2000;122:3236–3237.
17. (a) Lu J, Tan X, Chen C. *J Am Chem Soc* 2007;129:7768–7769. [PubMed: 17539649] See also: (b) Feldman KS, Skoumbourdis AP. *Org Lett* 2005;7:929–931. [PubMed: 15727477] (c) Ref. 15a; (d) Ref. 15b.
18. Besides Büchi's proposed formation of a C-10/N-14 linkage in ref. 15b for his dibromophakellin synthesis, it is also possible that a N-1/C-6 macrocycle, resembling Baran's palau'amine intermediate **4'** in ref. 6, was formed during the oxidation of **19**.
19. O'Malley DP, Li K, Maue M, Zografos AL, Baran PS. *J Am Chem Soc* 2007;129:4762–4775. [PubMed: 17375928]

Scheme 1.

The original (top) and revised (bottom) Kinnel–Scheuer biosynthesis of palau'amine.

Scheme 2.

The synthesis of **20**, a close analog of the Kinnel–Scheuer intermediate. (a) NaH, BOMCl, DMF, 23 °C, then NaH, CuCl₂, O₂, 23 °C, then POCl₃, 23 °C; 68%. (b) Ph₃P=CHCOOMe, benzene, 23 °C; 95%. (c) DIBAL, THF, 0 °C. (d) Cbz-β-Ala-OH, DCC, CH₂Cl₂, 23 °C. (e) LiHMDS, THF, −78 °C; 79% over three steps. (f) Dess–Martin periodinane, H₂O, CH₂Cl₂, 23 °C. (g) Mn(OAc)₃, HOAc, 60 °C; 36% over two steps. (h) LiOH, THF, H₂O, 23 °C. (i) (PhO)₂P(O)N₃, DEAD, PPh₃, THF, 23 °C; 42% over two steps. (j) LiHMDS, THF, then HOAc, −78→0 °C. (k) Ca(BH₄)₂, THF, 0 °C, then NaBH₃CN, HOAc, 50 °C. (l) TFA, CH₂Cl₂, 0 °C. (m) Dess–Martin periodinane, H₂O, CH₂Cl₂, 23 °C. (n) HCl, MeOH, H₂O, 40 °C, then *o*-(HO₂C)C₆H₄(CO₂K), NaOH, KOCN, 110 °C. (o) PPh₃, H₂O, THF, 80 °C; 7–10% over 6 steps. (p) (Br₂-Pyrrole)COCCl₃, NEt₃, DMF, 70 °C; 33%. (q) PhIO, Na₂CO₃, TFE, 23 °C. (r) DMSO, 50 °C; 20% over two steps.